SCHEMBL4304797

SCHEMBL4304797

CC(C)(C)OC(=O)Nc1ncsc1C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.45
PKM P14618 1/20 0.45
PSMB8 P28062 1/20 0.39
METAP1 P53582 1/20 0.38
ATR Q13535 1/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
NPSR1 Q6W5P4 1/20 0.36
LCK P06239 4/20 0.36
IRAK4 Q9NWZ3 1/20 0.35
CYP17A1 P05093 1/20 0.35
MEN1 O00255 1/20 0.34
NPC1 O15118 1/20 0.34
GAA P10253 1/20 0.34
RAB9A P51151 1/20 0.34
KMT2A Q03164 1/20 0.34
MAPT P10636 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25180969 0.87 ATR (0.45) KDM4EPSMB8METAP1ATRCA1
SCHEMBL12912412 0.83 NAMPT (0.46) METAP1LCKNPC1RAB9AKMT2A
SCHEMBL24114079 0.82 NPSR1 (0.38) KDM4EMETAP1ATRNPSR1LCK
SCHEMBL24114113 0.81 METAP1 (0.40) PSMB8METAP1ATRCA1CA2
SCHEMBL24114184 0.81 NPSR1 (0.38) KDM4EMETAP1ATRNPSR1LCK
SCHEMBL2051830 0.80 METAP1 (0.39) PSMB8METAP1ATRCA1CA2
SCHEMBL21644748 0.80 METAP1 (0.39) PSMB8METAP1ATRCA1CA2
SCHEMBL25179955 0.79 ATR (0.40) PSMB8METAP1ATRCA1CA2
SCHEMBL25179953 0.78 METAP1 (0.38) PSMB8METAP1ATRCA1CA2
SCHEMBL2520632 0.77 METAP1 (0.41) KDM4EPSMB8METAP1ATRCA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260041671-A1 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS INC (US) 2026-02-12 US disclosed
US-12539292-B2 BRM targeting compounds and associated methods of use ARVINAS OPERATIONS, INC. (US) 2026-02-03 US disclosed
EP-4038066-A1 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE Arvinas Operations, Inc. (US) 2022-08-10 EP disclosed
CN-114787159-A BRM targeting compounds and related methods of use 阿尔维纳斯运营股份有限公司 2022-07-22 CN disclosed
WO-2021067606-A1 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. (US) 2021-04-08 WO disclosed
WO-2021067606-A1 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. (US) 2021-04-08 WO disclosed
US-20200038378-A1 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE GENENTECH, INC. 2020-02-06 US disclosed
US-20200038378-A1 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE GENENTECH, INC. 2020-02-06 US disclosed
US-20110021541-A1 INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA ICOS CORPORATION 2011-01-27 US disclosed
US-20110021541-A1 INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA ICOS CORPORATION 2011-01-27 US disclosed
WO-2009064802-A2 INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA ELI LILLY & CO. (US) 2009-05-22 WO disclosed
US-20090023753-A1 1,3-Thiazole-5-Carboxamides Useful as Cancer Chemotherapeutic Agents BAYER HEALTHCARE AG (DE) 2009-01-22 US disclosed
US-20090023753-A1 1,3-Thiazole-5-Carboxamides Useful as Cancer Chemotherapeutic Agents BAYER HEALTHCARE AG (DE) 2009-01-22 US disclosed
US-20090023753-A1 1,3-Thiazole-5-Carboxamides Useful as Cancer Chemotherapeutic Agents BAYER HEALTHCARE AG (DE) 2009-01-22 US disclosed
CN-101133054-A 1, 3-thiazole-5-carboxamides useful as cancer chemotherapeutic agents BAYER PHARMACEUTICALS CORP (US) 2008-02-27 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12539292-B2 BRM targeting compounds and associated methods of use ADRM1, SUMO2, BAZ1A KDM4E 1905/4885PKM 2842/4885PSMB8 88/4885
US-20110021541-A1 INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA PIK3CD, PI4KB, PI4KA KDM4E 2922/4885PKM 1791/4885PSMB8 1841/4885
US-20200038378-A1 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE ADRM1, BRAP, VHL KDM4E 2143/4885PKM 2505/4885PSMB8 331/4885
US-20260041671-A1 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE ADRM1, VHL, BAZ1A KDM4E 2046/4885PKM 2978/4885PSMB8 266/4885
US-20090023753-A1 1,3-Thiazole-5-Carboxamides Useful as Cancer Chemotherapeutic Agents MCL1, HDAC5, HDAC6 KDM4E 1674/4885PKM 2925/4885PSMB8 4115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.